These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31899313)

  • 21. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
    Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
    Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
    Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
    Hachad H; Ramsey LB; Scott SA
    Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
    [No Abstract]   [Full Text] [Related]  

  • 28. Recent changes to FDA-approved labeling.
    Am J Health Syst Pharm; 2004 Sep; 61(17):1766. PubMed ID: 15462244
    [No Abstract]   [Full Text] [Related]  

  • 29. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs.
    Zineh I; Gerhard T; Aquilante CL; Beitelshees AL; Beasley BN; Hartzema AG
    Pharmacogenomics J; 2004; 4(6):354-8. PubMed ID: 15483659
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
    Christian C; Borden BA; Danahey K; Yeo KJ; van Wijk XMR; Ratain MJ; O'Donnell PH
    Clin Pharmacol Ther; 2020 Aug; 108(2):368-376. PubMed ID: 32236960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
    Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
    Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of pharmacogenomics in product information.
    Skvrce NM; Krivokapić S; Božina N
    Pharmacogenomics; 2020 May; 21(7):443-448. PubMed ID: 32336208
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
    Wang B; Canestaro WJ; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applications of pharmacogenomics in regulatory science: a product life cycle review.
    Tan-Koi WC; Leow PC; Teo YY
    Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What drug labels don't tell you.
    Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).
    Just KS; Steffens M; Swen JJ; Patrinos GP; Guchelaar HJ; Stingl JC
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1247-1252. PubMed ID: 28669097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacology at the start of a new millennium. Larger assortment and individual drug dosing are coming].
    Fredholm BB; Sjöqvist F
    Lakartidningen; 2001 Feb; 98(6):534-9. PubMed ID: 11475239
    [No Abstract]   [Full Text] [Related]  

  • 39. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.